Biotech & Pharma

Clinical trial catalysts, FDA decisions, and drug-development micro-caps.

1 article

Novo Nordisk Just Validated a $108 Million Micro-Cap's Implant Technology

Biotech & Pharma

★ FEATURED

Novo Nordisk Just Validated a $108 Million Micro-Cap's Implant Technology

Vivani Medical, a roughly $108 million clinical-stage biopharma, just landed an evaluation agreement with Novo Nordisk for its ultra-long-acting semaglutide implant — real validation from one of the biggest names in weight-management drugs, with almost no promotional noise to go with it.

Hidden Value / Deep Value

ASSET QUALITY8/10

PROMO INTENSITY5/10

via StockTitan — "Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139"2026-07-07